MacroGenics (NASDAQ:MGNX – Get Free Report) and Modular Medical (NASDAQ:MODD – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.
Volatility and Risk
MacroGenics has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Modular Medical has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500.
Institutional and Insider Ownership
96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 27.5% of Modular Medical shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by insiders. Comparatively, 7.1% of Modular Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MacroGenics | 1 | 3 | 3 | 0 | 2.29 |
| Modular Medical | 1 | 0 | 0 | 0 | 1.00 |
MacroGenics currently has a consensus target price of $5.50, indicating a potential upside of 38.89%. Given MacroGenics’ stronger consensus rating and higher probable upside, research analysts clearly believe MacroGenics is more favorable than Modular Medical.
Profitability
This table compares MacroGenics and Modular Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MacroGenics | -44.79% | -147.80% | -28.40% |
| Modular Medical | N/A | -245.85% | -190.80% |
Earnings and Valuation
This table compares MacroGenics and Modular Medical”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MacroGenics | $149.50 million | 1.68 | -$74.62 million | ($1.10) | -3.60 |
| Modular Medical | N/A | N/A | -$18.82 million | ($14.71) | -0.32 |
Modular Medical has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Modular Medical, indicating that it is currently the more affordable of the two stocks.
Summary
MacroGenics beats Modular Medical on 10 of the 13 factors compared between the two stocks.
About MacroGenics
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
About Modular Medical
Modular Medical, Inc. operates as a medical device company. It focuses on the design, development, and commercialization of insulin pumps. It offers MODD1, a two-part patch pump for type-1 and type-2 diabetes. The company is headquartered in San Diego, California.
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.
